Targeting the epigenome for the treatment of thoracic malignancies.
Despite considerable efforts to improve the diagnosis and treatment of lung cancer, this disease remains the leading cause of cancer-related mortality worldwide. Recent elucidation of epigenetic regulation of gene expression during malignant transformation, together with the identification of agents that modulate DNA methylation and histone acetylation, provide new opportunities for the treatment and prevention of lung cancer via chromatin remodeling mechanisms. Further analysis of molecular response in tumor tissues following exposure to chromatin remodeling agents may enable us to identify novel mechanisms pertaining to lung cancer epigenetics, and design more efficacious regimens.
Schrump
David S
DS
Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, Room 4-3940, 10 Center Drive, MSC 1201, Bethesda, MD 20892-1201, USA. david_schrump@nih.gov
Nguyen
Dao M
DM
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use; D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D002843:Chromatin / Q000378:metabolism; D000077209:Decitabine; D047630:Depsipeptides / Q000494:pharmacology / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D044127:Epigenesis, Genetic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D002843:Chromatin; D047630:Depsipeptides; D000077209:Decitabine; C087123:romidepsin; D001374:Azacitidine